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Background: Transmitted drug-resistance (TDR) remains a critical aspect for the management of HIV-1-infected
individuals. Thus, studying the dynamics of TDR is crucial to optimize HIV care.
Methods: In total, 4323 HIV-1 protease/reverse-transcriptase sequences from drug-naive individuals diagnosed in
north and central Italy between 2000 and 2014 were analysed. TDR was evaluated over time. Maximum-likelihood
and Bayesian phylogenetic trees with bootstrap and Bayesian-probability supports defined transmission clusters.
Results: Most individuals were males (80.2%) and Italian (72.1%), with a median (IQR) age of 37 (30–45) years.
MSM accounted for 42.2% of cases, followed by heterosexuals (36.4%). Non-B subtype infections accounted for
30.8% of the overall population and increased over time (,2005–14: 19.5%–38.5%, P,0.0001), particularly
among Italians (,2005–14: 6.5%–28.8%, P,0.0001). TDR prevalence was 8.8% and increased over time in non-
B subtypes (,2005–14: 2%–7.1%, P"0.018). Overall, 467 transmission clusters (involving 1207 individuals;
27.9%) were identified. The prevalence of individuals grouping in transmission clusters increased over time in
both B (,2005–14: 12.9%–33.5%, P"0.001) and non-B subtypes (,2005–14: 18.4%–41.9%, P"0.006).
TDR transmission clusters were 13.3% within the overall cluster observed and dramatically increased in recent
years (,2005–14: 14.3%–35.5%, P"0.005). This recent increase was mainly due to non-B subtype-infected indi-
viduals, who were also more frequently involved in large transmission clusters than those infected with a B sub-
type [median number of individuals in transmission clusters: 7 (IQR 6–19) versus 4 (3–4), P" 0.047].
Conclusions: The epidemiology of HIV transmission changed greatly over time; the increasing number of trans-
mission clusters (sometimes with drug resistance) shows that detection and proper treatment of the multi-
transmitters is a major target for controlling HIV spread.
Introduction
HIV-1 transmitted drug resistance (TDR) is a clinical and public
health issue due to its role in compromising the response to ART at
the individual and population level,1–4 limiting the antiretroviral
regimen options. As a result, European and US guidelines recom-
mend genotypic resistance testing in HIV-infected individuals at
entry into care (regardless of whether ART will be initiated
immediately).5,6
To date, estimates of TDR rates vary across the world and range
from 3.4% to 25.2% in the USA,7–9 and from 7.5% to 11.7% in
Europe.10–13 Despite the general decreasing trend of TDR in both
the United States and Europe in the last few years, an alarming in-
crease has been noticed in some specific settings.7,14 In this re-
gard, in several countries different frequencies of TDR, according to
subtypes and risk factors, have been observed, especially in the
last decade, when an increase in non-B subtypes and circulating
recombinant forms (CRFs) has been reported.15–17 This increase in
non-B subtypes occurred in conjunction with associated epidemio-
logical changes such as waves of migration from low-income to
middle-income areas,18,19 and the increase of HIV transmission
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rate among MSM,20,21 which to date accounts for at least 43% of
new HIV-1 cases.22,23
In this scenario, studying the linkages between viruses
through transmission cluster (TC) analysis can be used to
provide an in-depth understanding of TDR dynamics and resist-
ance spread.11,24,25 For these reasons, this study aims to
characterize the dynamics and phylogenetic relationships of
TDR and subtypes among a large cohort of HIV-1-infected
individuals diagnosed in Italy from 2000 to 2014.
Methods
Study population
Between 2000 and 2014, plasma samples from 4323 newly diagnosed
HIV-1-infected individuals, naive to ART, attending three different counsel-
ling and testing centres in north and central Italy, were tested for antiretro-
viral drug resistance (DR) genotyping, according to routine clinical practice.
Individuals were defined as recently infected by: (i) clinical/laboratory
signs of primary HIV infection (HIV-1 RNA levels .10000 copies/mL and
negative or indeterminate HIV-1 antibody test); (ii) a documented negative
HIV-1 test performed within 6 months before the HIV-1 diagnosis; and
(iii) an antibody avidity index 0.80 (test performed only in clinically AIDS-
free individuals).26,27
All clinical and virological information used in this study was collected
within 8 weeks after the initial HIV-1 diagnosis (range of weeks after HIV-1
diagnosis: 0–8).
Ethics
This study was approved by the ethics committee of Tor Vergata Hospital
(Ethics Approval No. 238/16, 14 December 2016) and L. Spallanzani National
Institute for Infectious Diseases, IRCCS (Ethics Approval No. 51, 18 December
2003). The research was conducted on anonymous samples in accordance
with the principles of the Declaration of Helsinki and the Italian Ministry of
Health. All information, including virological and clinical data, was recorded
in an anonymized database.
HIV-1 genotyping
For all individuals HIV-1 pol [containing the full-length protease (PR) and
the first 335 reverse transcriptase (RT) codons] sequences were available at
the time of diagnosis (range 0–2 months from diagnosis). HIV-1 pol geno-
type analyses were performed on plasma samples, as previously
described.28 All samples were processed immediately upon arrival in clinical
laboratories.
HIV-1 subtyping
For each HIV-1-infected individual, the HIV-1 subtype was determined. pol
sequences were aligned and compared with reference sequences for the
major HIV-1 subtypes, available at: https://www.hiv.lanl.gov/content/se
quence/NEWALIGN/align.html#ref, using CLUSTAL X. The sequences were
then manually edited with the Bioedit program, and gaps were removed
from the final alignment. Subtype or CRF assignments were achieved by con-
structing phylogenetic trees using the neighbour-joining (NJ) method.29
Distances were calculated using MEGA 6 based on the Kimura two-parameter
model.30 The reliability of the branching orders was assessed by bootstrap
analysis of 1000 replicates.
Definition of TDR
TDR was evaluated by considering the WHO-2009 list31 with the additional
RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C
and M230I, reported in the International AIDS Society (IAS) list32 and/or
the Stanford 2017 database (https://hivdb.stanford.edu/, last updated
7 February 2017).
HIV-1 strains were defined as resistant if carrying at least one TDR
mutation.
Transmission cluster analysis
TCs, including pairs (2 individuals) and clusters (3 individuals) were first
deduced by the NJ method by using all the 4323 pol sequences obtained
via routine clinical practice in the period 2000–14. To avoid any possibility of
cross-contamination, identical sequences amplified in the same run were
excluded. To avoid the influence of convergent evolution at antiretroviral
DR mutations, sequences were stripped at positions related to DR.
Only clusters with a bootstrap value.90% and an average genetic distance
,0.015 were selected.33
The robustness of the TCs was further tested using the maximum likeli-
hood (ML) method and a Bayesian analysis.
The ML tree was inferred with the general time-reversible nucleotide
substitution model (GTR) with gamma-distribution among site rate hetero-
geneity, a proportion of invariable sites (GTR! I!U5)
34 and 1000 bootstrap
replicates (using the RaxML software, available at http://sco.h-its.org/exe
lixis/web/software/raxml/index.html). TCs were recognized by Cluster
Picker,35 retrieved at http://hiv.bio.ed.ac.uk/software.html, based on a boot-
strap value .90% and an average genetic distance ,0.015. The tree was
rooted using a midpoint rooting by FigTree software version 1.4.2.
The Bayesian phylogenetic tree was reconstructed with MrBayes,36
using a GTR! I!U5. A Monte Carlo Markov chain search was run for 5%10
6
generations with the trees sampled every 100th generation (with a burn-in
of 50%).37 Statistical support was obtained by calculating the posterior
probability of each monophyletic clade, and an a posteriori consensus tree
was generated after 50% burn-in. Clades were considered epidemiological
clusters only if a posterior probability of 1 was inferred.
Statistical analysis
To evaluate potential differences in the prevalence of TDR according to sub-
type, the v2 test or Fisher’s exact test was used, as appropriate. Potential
differences in the prevalence of TDR, subtypes and risk factor over the years
2000–14 were evaluated by time-series analysis for linear trend. The 251 in-
dividuals diagnosed between 2000 and 2004 were gathered together in a
single time period defined as ,2005, in order to have a similar numerical
distribution of individuals over the years.
Factors associated with TDR (in both the overall population and within
clusters) were evaluated by uni-multivariable logistic regression analysis,
using as confounders gender, age, subtype, risk factor, nationality, year of
diagnosis and sequencing, viraemia and CD4 count at sequencing, type of
infection and to be part of TC.
For all statistical tests, the level of significance for the evaluation of
two-sided P values was set at a"0.05. All the analyses were performed by
using the R open source statistical environment (version 3.3.1) and SPSS
(version 23) for Windows (SPSS Inc., Chicago, Illinois).
Results
Patient characteristics
A total of 4323 individuals newly diagnosed with HIV-1 from 2000
through 2014 were included (Table 1). The majority of these indi-
viduals (3468, 80.2%) were male, Italian (3115, 72.1%) and MSM
(1824, 42.2%). Recent infections accounted for the 22.5% of the
individuals for whom state of infection was available.
The majority (N"2992, 69.2%) of the individuals were infected
with a B subtype, followed by CRF02_AG (329, 7.6%), F1 (248, 5.7%),
Fabeni et al.
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and C (219, 5.1%). The remaining individuals were infected
with other pure subtypes or CRFs (535, 12.4%). An increase in non-B
HIV-1 subtype infections was found over time (,2005–14:
19.5%–38.5%, P,0.0001) (Figure 1a). Of note, the proportion of non-
B subtypes progressively rose in Italians (,2005–14: 6.5%–28.8%,
P,0.0001) (Figure 1b). Regarding risk factors, while individuals
infected with B subtype were predominantly MSM (1487, 49.7%),
non-B subtype-infected individuals mainly reported heterosexual
contact (709, 53.3%) (Table 1). However, looking at the dynamics of
risk factors in the non-B-infected population, a significant increase
was observed in the MSM over time (,2005–14: 20.0%–36.0%,
P,0.0001). This phenomenon is strictly related to the recent increas-
ing proportion of Italian MSM in this non-B population (,2005–14:
50.0%–80.4%, P"0.047). Interestingly, the prevalence of MSM
also increased over time in the 403 recent infections (,2005–14:
45.5%–78.6%, P,0.0001).
Prevalence and temporal trend of transmitted
drug resistance
The overall prevalence of TDR in the period 2000–14 was 8.8%
(N"382). The majority of individuals carried a single mutation
(N"266, 69.6%). TDR was higher in B subtype-infected individuals
than in those infected with non-B subtypes (9.7% versus 6.9%,
P" 0.003). By analysing individuals carrying TDR and with an
available state of infection, 38 (26.2%) were in recent infections.
Of these, 24 (63.1%) were MSM and 12 (31.6%) were heterosexual
transmissions.
Analysing the TDR temporal trend, in B subtype-infected individ-
uals resistance to any drug class decreased over time with a slight
trend towards significance (,2005–14: 13.4%–8.1%, P"0.156),
with a significant decrease in DR to PIs (,2005–14: 5.0%–1.6%,
P"0.001) (Figure 2a). In contrast, among the 1331 non-B subtype-
infected individuals, TDR to any drug class significantly increased
over time (,2005–14: 2%–7.1%, P"0.018) (Figure 2b).
Transmission clusters and their role in TDR
Overall, we identified 467 TCs, involving 1207 of the 4323 newly
diagnosed individuals analysed (27.9%). Among B subtype-
infected subjects, 259 pairs and 82 TCs with 3 individuals were
identified, while 86 pairs and 40 TCs (3 individuals) were detected
in non-B subtype-infected individuals.
Even if the prevalence of sequences grouping in TCs was only
27.9%, an increasing proportion of individuals in B subtype TCs
(,2005–14: 12.9%–33.5%, P"0.001) and non-B subtype TCs
(,2005–14: 18.4%–41.9%, P"0.006) was observed over time
(data not shown).
With regard to characteristics of individuals involved in TCs,
women and heterosexuals were more frequently found in non-B
subtype TCs than in B subtype TCs (22.4% versus 12.1%,
P,0.0001, and 42.1% versus 25.4%, P,0.0001, respectively).
Table 1. Patient characteristics
Characteristic Overall (N"4323) B (N"2992) Non-B (N"1331) P valuea
Male, n (%) 3468 (80.2) 2548 (85.2) 920 (69.1) ,0.001
Geographic area, n (%)
Italy 3115 (72.1) 2492 (83.3) 623 (46.8) ,0.001
Africa 446 (10.3) 45 (1.5) 401 (30.1) ,0.001
Europe 355 (8.2) 182 (6.1) 173 (13.0) ,0.001
America 328 (7.6) 240 (8.0) 88 (6.6) 0.106
Asia/Australia/Oceania 79 (1.8) 33 (1.1) 46 (3.5) ,0.001
Risk factor, n (%)
MSM 1824 (42.2) 1487 (49.7) 337 (25.3) ,0.001
heterosexual 1573 (36.4) 864 (28.9) 709 (53.3) ,0.001
drug user 177 (4.1) 133 (4.4) 44 (3.3) 0.097
others/unknown 749 (17.3) 508 (17.0) 241 (18.1) 0.384
Age (years), median (IQR) 37 (30–45) 38 (31–45) 36 (29–43) ,0.001
CD4 cell count (cells/mm3), median (IQR) 321 (132–510) 331 (131–552) 304 (132–486) 0.006
Viral load (log10 copies/mL), median (IQR) 4.9 (4.3–5.4) 4.9 (4.3–5.4) 4.9 (4.3–5.5) 0.07
Year of diagnosis, median (IQR) 2010 (2007–12) 2009 (2007–12) 2011 (2008–12) ,0.001
Year of GRT, median (IQR) 2010 (2007–12) 2010 (2007–12) 2011 (2008–12) ,0.001
State of infection, recent, n (%)b 403 (22.5) 284 (22.0) 119 (23.7) 0.45
Patients with TDR, n (%) 382 (8.8) 290 (9.7) 92 (6.9) 0.003
Patients with NRTI TDR, n (%) 152 (3.5) 134 (4.5) 18 (1.4) ,0.001
Patients with NNRTI TDR, n (%) 180 (4.2) 124 (4.1) 56 (4.2) 0.924
Patients with PI TDR, n (%) 101 (2.3) 75 (2.5) 26 (1.9) 0.316
Patients in TCs, n (%) 954 (22.1) 683 (22.8) 271 (20.4) 0.071
GRT, genotypic resistance test; TDR, transmitted drug resistance; TCs, transmission clusters.
aBy v2 test or Fisher’s exact test, as appropriate (qualitative variables) and Wilcoxon–Mann–Whitney (quantitative variables).
bData available for 1292 B and 502 non-B subtype-infected individuals.
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Moreover, individuals in non-B subtype TCs were diagnosed in
more recent years compared with those involved in B subtype TCs
[2011 (2009–13) versus 2010 (2008–12), P,0.0001]. Considering
the state of infection, 58.5% of recent infections in TCs involved
MSM, while only 31.9% involved heterosexuals (P"0.11).
Looking at resistance, 13.3% of TCs (N"62; B subtype: N"44,
non-B subtypes: N"18) involved at least one subject with
TDR (112 individuals, 29.3% of the entire TDR population)
(Figures S1 and S2, available as Supplementary data at JAC
Online). Of these 62 TCs, 48 (B subtype: N"35; non-B subtypes:
N"13) were pairs, and 14 (B subtype: N"9; non-B subtypes:
N"5) were TCs with 3 individuals. Moreover, among these
62 TCs, 24 (38.7%) included a single patient with TDR, while
32 (51.6%) were entirely composed of individuals carrying resist-
ance (Table S1).
By analysing the rate of TDR clustering over time, the presence
of TDR within TCs dramatically increased over the years, reaching
35.5% of the overall TDR in 2014 (,2005–14: 14.3%–35.5%,
P" 0.005) (data not shown).
Considering the characteristics of the 190 subjects involved in
the 62 TDR TCs, 86.3% (N"165) were male, 79.5% (N"151) were
Italians and 49.5% (N"94) were MSM (Table S1). By comparing
the characteristics between B and non-B subtype TDR TCs, non-B
subtype-infected subjects were diagnosed in more recent years
[2012 (2010–13) versus 2009 (2008–12), P,0.0001], and
more frequently involved in large TCs [median 7 (IQR 6–19) versus
4 (3–4), P"0.047] compared with individuals infected with a B sub-
type. No statistically significant differences were found in the time
of infection (recent or long-standing), nationalities or risk factors.
Prevalence of TDR mutations in the overall population
and in the TCs
The prevalence of TDR mutations in the overall population and in
the TCs according to drug classes and subtypes is shown in
Figure 3.
Analysing resistance in HIV-1 B subtype-infected individuals,
4.5% of them (134/2992) harboured mutations associated with re-
sistance to NRTIs; of note, 1.4% of these individuals (41/2992)
were involved in TCs. The NRTI mutation T215rev had the highest
prevalence in the overall B subtype-infected population (3.1%: in-
dividuals involved in TCs, 0.9%; individuals not included in TCs,
2.2%), followed by M41L (1.6%: 0.6% and 1%) and L210W (1.0%:
0.3% and 0.7%). Interestingly, in non-B subtype-infected individ-
uals NRTI mutations accounted only for 1.4% of the overall popu-
lation; none of these mutations were found in TCs.
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Figure 1. Evaluation of B and non-B subtype prevalence in HIV-1-infected individuals over time in the overall population (a) and in Italians (b). P val-
ues (calculated by time series analysis for linear trend over time) were both significant (P,0.0001).
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Concerning NNRTI resistance, 4.1% (124/2992) and 4.2%
(56/1331) of the B and non-B subtype infected individuals carried
at least one mutation to this class, respectively. Of note, 1.0% of
B (31/2992) and 1.9% of non-B (25/1331) subtype-infected individ-
uals were involved in TCs.
In both B and non-B subtype groups, the most prevalent NNRTI
mutations (either in individuals included or in those non-included
in TCs) were K103N (B subtype: 2.1%; non-B subtype: 1.7%) and
E138G/K (0.7%; 1.7%), followed by K101E (0.7%; 0.8%).
In the overall B and non-B subtype groups, mutations associ-
ated with resistance to PI were observed with a prevalence 2.5%
(individuals involved in TCs: 0.6%; individuals not included in TCs:
1.9%) and 2.0% (0.7%; 1.3%); Q58E was the most prevalent PI
mutation found both in the overall B and non-B groups.
Factors associated with TDR
Univariate and multivariate logistic regression models were per-
formed to identify potential predictors of TDR (Figure 4).
The results showed that in our population, being part of TCs was
not a predictor of TDR [adjusted odds ratio, AOR (95% CI): 0.92
(0.71–1.18); P"0.495]. Whereas there was a negative association
between the presence of TDR and individuals infected with a
CRF02_AG recombinant form compared with those infected with a
B subtype [AOR (95% CI): 0.45 (0.26–0.80); P"0.006]. These
results were also confirmed by using the type of infection as a con-
founder (N"1794), (Figure 4b).
Discussion
We have here described molecular and epidemiological character-
istics of 4323 HIV-1 drug-naive infected individuals attending three
different counselling and testing centres in north and central Italy
in the period 2000–14 to gain further insights into the time trends
of subtype distribution, TDR and TCs.
The first finding concerns the epidemiological changes occurring
in Italy over the last decade. In particular, our study, which covers a
period of 14 years, observed a higher prevalence of non-B subtypes
in newly diagnosed individuals, and, mainly, in subjects originating
from Italy. This is in line with the important increase of non-B
subtypes and CRFs reported in several European countries15,38–43
during the last decade. This increase in non-B subtypes occurred in
conjunction with associated epidemiological changes, such as
waves of migration from low-income to middle-income areas,18,19
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Figure 2. Prevalence of transmitted drug resistance (TDR) in Italian HIV-1-infected individuals, diagnosed in the period 2000–14, according to calen-
dar year and drug classes. (a) Prevalence of TDR over time in individuals infected with HIV-1 B subtype. (b) Prevalence of TDR over time in individuals
infected with HIV-1 non-B subtypes. The P value was calculated by time-series analysis for linear trend over time (only significant values are shown).
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Figure 3. Prevalence of drug resistance mutations in HIV-1 B (a) and non-B subtypes (b) according to drug classes and presence or not in transmis-
sion clusters (TCs). Each bar is divided according to: (i) the presence of drug resistance mutations in clusters with 3 sequences (black bar); (ii) the
presence of drug resistance mutations in pairs (hatched bar); (iii) the presence of drug resistance mutations out of clusters (white bar). ‘Other’ in-
cludes all the resistance mutations with an overall prevalence ,0.2%.
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Figure 4. (a) Multivariable logistic regression model performed on the overall population analysed. The model was adjusted for gender, age, subtype,
risk factor, nationality, year of diagnosis, year of genotypic resistance testing (GRT), viral load at GRT (log10 copies/mL), CD4 cell count at GRT
(cells/mm3), and being part of a transmission cluster (TC). (b) Multivariable logistic regression model performed on a subset of individuals (N"1794,
with similar characteristics of the overall population) for whom type of infection (recent or chronic) was known. The model was adjusted for the same
variables included in the model shown in (a) and the type of infection.
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and an increase in HIV transmission among MSM.20,44–49 In line
with this phenomenon, our study also shows that the non-B epi-
demic is characterized by a shift in the prevalent modality of infec-
tion and nationality, and also in the setting of recent infection.
Based on these findings, we analysed the dynamics of TDR accord-
ing to these temporal epidemiological changes.
The overall TDR prevalence was 8.8%, consistent with other
European studies,11–13,50,51 but lower than that observed in several
US settings.8,9 However, an alarming temporal TDR increase
was observed in subjects infected with non-B subtype HIV-1
(,2005–14: 2.0%–7.1%, P"0.018), different from that observed
in HIV-1 B-infected individuals. This increasing trend of TDR in non-
B subtypes observed in our population coincided with an increase
in recent infections characterized by a homosexual transmission
route. This finding was also reported by a recent paper published
by our group,20 highlighting circulation of TDR TCs characterized by
non-B MSM. Other European studies confirmed the strict relation-
ship between the increasing trend of TDR and the MSM route, in
non-B infections,49,51 but also in subtype B infections.11 These data
highlight the importance of studying and monitoring local epi-
demics and suggests TDR prevalence may vary within subtypes
and risk factors.
By assessing TDR prevalence according to drug class, we found
that the increasing trend in non-B TDR is mainly linked to the detec-
tion of NNRTI DR, as also suggested by the high prevalence of K103N
and K101E in the overall and TC populations. The same linear in-
crease was observed in the SPREAD study that included data up to
2007,52 in which the authors suggested a potential association with
the frequent use of NNRTI in the first-line regimens. Indeed, from
2009 onwards, the most commonly prescribed regimen was the po-
tent combination tenofovir! emtricitabine! efavirenz, and up until
2012, no other available regimens had proven superior to this one
with respect to the virological response.
The second aim of this study was to evaluate the contribution
of TCs in the spread of the HIV epidemic and TDR. In this study, the
rate of sequences segregating in clusters is 28.0%, similar to that
reported in France,40 the Basque country53 and the UK,54 and quite
low with respect to that reported in the Nordic European coun-
tries41 and in the Swiss cohort.54
The presence of TDR within TCs accounted for 29.3% of the en-
tire TDR population. The contribution of TCs to TDR observed was
superimposable onto those reported by other European and US
studies,7,11 especially when a more stringent criterion of genetic
distance for TC detection was applied.11 Most importantly, our
study indicates that the contribution of TCs to the spread of DR has
increased in the last few years, with a peak in 2014, suggesting
that a public health policy targeting early diagnoses is needed.
Since multivariate logistic regression models did not identify fac-
tors associated with TDR, with the exception of a negative role of
CRF02_AG, we were unable to identify positive predictors of DR, a
result similar to that observed in other studies performed in
Europe.11,14 In line with other European cohorts, our TDR TCs fre-
quently involved individuals with different subtypes and national-
ities.11,20 This implies that migration plays an important role in the
local spread of B and non-B subtypes, but also of TDR, supporting
an extensive intermixing of the HIV-1 epidemic between locals
and immigrants.
Moreover, as reported above, the spread of non-B subtypes in
the local epidemic and in TCs was an increasing phenomenon,
mainly related to the MSM route that often involves Italians. The
contribution of MSM in TCs was also evident when recent infections
were considered. In particular, 30.3% of MSM in our TC population
was recently infected and this prevalence increased to 44.4%
when non-B TCs were considered. The high propensity of MSM for
clustering was previously reported by Ragonnet-Cronin et al.,54
who found a predominant MSM contribution in TCs for both the UK
HIV Drug Resistance Database and the Swiss HIV Cohort Study.
Regarding TDR in TCs, NRTIs, and in particular the T215 revert-
ant mutations, were predominant in B subtype TCs, confirming the
frequent transmission of viruses containing revertants at position
215 in Europe.11,33 In contrast, we did not find any resistance mu-
tations associated with thymidine analogues (such as T215rev,
M41L and L210W) in non-B TCs. This finding may be explained by
the more recent date of diagnosis found in non-B versus B sub-
types, occurring when the use of thymidine analogues was no lon-
ger recommended.
In non-B TCs, the predominant role in the spread of TDR was
played by NNRTI mutations (in particular K103N, E138K and
K101E). In fact, one of the most important TCs carried K103N
(shown in Figure S2). This cluster involved both heterosexual and
homosexual males originating from Italy. The latest diagnosis
date was 2014, suggesting that in our local epidemic this mutation
was involved in a recent spread.
Thus, continuous monitoring of the role of NNRTI mutations in
TCs is required to establish their impact on current HIV epidemics.
As with any other observational study, our data may have
some limitations. First, our study population might not be repre-
sentative of the overall Italian population. In particular, looking at
the HIV/AIDS surveillance reports published by ECDC and the WHO
Regional Office for Europe (WHO/Europe),22 37023 new diagnoses
of HIV-1 were reported in Italy from 2005 to 2015. Thus, the
4323 HIV-1 diagnoses reported in our study in the same time
period represent 11.7% of the overall HIV-1-infected Italian popu-
lation. Focusing attention on the new diagnoses found in north
and central Italy (N"22798), this coverage increased to 19.0% of
the overall HIV-1-infected individuals.55 However, the increasing
prevalence of non-B subtypes and MSM found in our population
over time (also in the setting of recent infections) is confirmed by
the high prevalence of immigrants and MSM reported in 2015,55
thus suggesting that our samples broadly matched the character-
istics of the whole HIV-1-infected Italian population. The increas-
ing trend of non-B and MSM was also reported by several European
studies,41,44,48,49 suggesting a good reproducibility of our results
with respect to large European contexts, and supporting the role of
migration in the epidemiological changes described above.
Second, this study did not evaluate TDR to other classes of anti-
retroviral drugs, such as integrase inhibitors. As the use of these
agents increases and is recommended by national and interna-
tional guidelines,5,56,57 surveillance for TDR must be included.
Finally, the potential association between demographic data and
TDR could not be evaluated in depth because some information
was not available.
In conclusion, this study proves that complementing informa-
tion on individuals’ demographics, modality of transmission, viral
and clinical parameters, with results obtained through phylogen-
etic analysis, creates an added value in the understanding of local
HIV epidemics. In particular, with this study, we were able to show
that individuals infected with B subtype viruses and individuals
Dynamics of HIV-1 transmitted drug resistance in Italy JAC
2843
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/72/10/2837/3979534 by D
ivisione C
oordinam
ento delle Biblioteche - U
niv. di M
ilano user on 21 M
arch 2019
infected with non-B subtypes represent significantly different
populations, with different routes of transmission and different
trends of TDR. This study also suggests that HIV-1 non-B subtypes
in Italy may have a primary role in the spread of drug-resistant
strains, which have to date mainly been associated with the B sub-
type. Indeed, TDR and complex TCs containing drug-resistant
strains, to date observed mainly in the context of B subtype infec-
tions, dramatically increased in HIV-1 non-B-infected individuals.
Overall, this deeper analysis can contribute to the design of
well-targeted prevention and control programmes, and to re-
inforce the current recommendation for both baseline resistance
testing to guide treatment decisions and early treatment in order
to prevent transmission of HIV drug resistance.5,6
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